Sign in
CompletedNo phase

Impact of NR3C1 rs41423247 (BclI) Polymorphism on Disease Severity in Alopecia Areata

Key facts

Who runs it
Benha University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
120 people enrolled
Started
1 Nov 2023
Ended
1 Dec 2024
Type of study
Observational, 2 groups
Record updated
6 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Clinically diagnosed alopecia areata
  • Age ≥ 18 years
  • Both sexes
  • Willingness to participate and provide informed consent
  • Apparently healthy individuals
  • No history of autoimmune disease
  • Age- and sex-matched to cases
  • Provided informed consent

Who cannot take part

  • Current systemic immunosuppressive therapy
  • Presence of other autoimmune or inflammatory diseases
  • Pregnancy or lactation
  • Refusal to participate

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Alopecia areata is an autoimmune, non-scarring hair loss disorder with multifactorial pathogenesis. The glucocorticoid receptor gene (NR3C1) plays an essential role in immune regulation and inflammatory response. The rs41423247 polymorphism (BclI) may influence glucocorticoid sensitivity and disease activity. This study aims to investigate the association between NR3C1 rs41423247 polymorphism and susceptibility to alopecia areata and to evaluate its correlation with disease severity using the Severity of Alopecia Tool (SALT) score.

The 2 groups in the trial

  • Group 1: Alopecia Areata Patients

    Participants diagnosed clinically with alopecia areata (n = 60). Peripheral blood samples will be collected for genetic analysis of NR3C1 rs41423247 polymorphism. Disease severity will be assessed using SALT score.

  • Group 2: Healthy Controls

    Age- and sex-matched healthy individuals without autoimmune disease (n = 60). Peripheral blood samples will be collected for genetic analysis of NR3C1 rs41423247 polymorphism.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessment of Glucocorticoid Receptor Gene Polymorphism in Alopecia Areata
Record updated
6 March 2026